TrialInternational journal of clinical oncology2018

Feasibility of dose-dense epirubicin and cyclophosphamide with subcutaneous pegfilgrastim 3.6 mg support: a single-center prospective study in Japan.

Sachi Morita et al.PubMed ↗Publisher ↗

No numbers read from the abstract.